MARINUS PHARMACEUTICALS INCBusiness Directories,Company Directories

Company Name: Corporate Name:	MARINUS PHARMACEUTICALS INC
Company Title:	Marinus Pharmaceuticals, INC
Company Description:
Keywords to Search:
Company Address:	21 Business Park Dr,BRANFORD,CT,USA
ZIP Code: Postal Code:	06405-2935
Telephone Number:	2033150566 (+1-203-315-0566)
Fax Number:	2033150566 (+1-203-315-0566)
Website:	www. marinuspharma. com
Email:
USA SIC Code(Standard Industrial Classification Code):	512203
USA SIC Description:	Pharmaceutical Products-Wholesale
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
TRIAD COMPUTER SOLUTIONS
UCONN INSURANCE LAW CENTER
ALL COUNTIES/OCONNOR INSURANCE

Next company profile:
ERA FORT HALE SHORELINE
PREMIER SUBARU
DUNKIN DONUTS

Company News:

Marinus Pharmaceuticals, Inc. - News
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
Immedica completes acquisition of Marinus Pharmaceuticals, Inc.
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders Marinus’ product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the United States in 2022
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares . . .
As per the deal, Immedica will launch a tender offer through a wholly owned subsidiary to acquire all outstanding shares of Marinus common stock at $0 55 per share in cash
Acquisition | MARINUS PHARMACEUTICALS INC | 11th February 2025
Initially announced on December 30, 2024 Immedica Pharma AB made a cash offer for MARINUS PHARMACEUTICALS INC of USD 0 55 per MARINUS PHARMACEUTICALS INC share held Pending the completion of customary closing conditions, the Acquisition is expected to be completed on February 11, 2025
Marinus Pharmaceuticals Inc - Reuters
The U S health regulator has approved Marinus Pharmaceuticals Inc's lead drug to treat seizures associated with a rare genetic disorder in patients two years of age and older, the company
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 . . . - MSN
STOCKHOLM, Sweden RADNOR, PA – Immedica Pharma AB has announced its plan to acquire Marinus Pharmaceuticals, Inc (Nasdaq: MRNS) in a transaction valued at approximately $151 million
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for USD 0 55 per share, corresponding to an implied enterprise value of approximately USD 151
Marinus Pharmaceuticals (MRNS) FDA Approvals - MarketBeat
Has Marinus Pharmaceuticals received FDA approval? Track FDA approvals, PDUFA dates, and regulatory milestones for MRNS with the latest event history at MarketBeat
Marinus Pharmaceuticals, Inc. - Immedica to Acquire Biopharmaceutical . . .
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders The Company’s product, ZTALMY ® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U S in 2022
Immedica successfully completes tender offer for all outstanding shares . . .
Immedica expects to complete the acquisition of Marinus on February 11, 2025, through a merger without a vote or meeting of Marinus’ stockholders pursuant to Section 251 (h) of the General Corporation Law of the State of Delaware